ESSEX, Conn.--(BUSINESS WIRE)--Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to ...
Morningstar brands and products Company Portfolio ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback